The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImperial Innovations Group Regulatory News (IVO)

  • There is currently no data for IVO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) - Touchstone Innovations Plc

13 Sep 2017 09:33

RNS Number : 6221Q
Numis Securities Limited
13 September 2017
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Numis Securities Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

 

Touchstone Innovations PLC

 

(c) Name of the party to the offer with which exempt principal trader is connected:

Sponsor, Broker and Joint Financial Adviser to IP Group PLC

 

(d) Date dealing undertaken:

12/09/2017

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

 

Yes

IP Group PLC

 

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

3 1/33p ordinary

 

Purchase

N/A

N/A

N/A

3 1/33p ordinary

 

Sale

2,000

255.00 GBX

255.00 GBX

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

3. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

 

 

Date of disclosure:

13/09/2017

Contact name:

Jessica Meta

Telephone number:

0207 260 1330

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERGIGDCBXBBGRX
Date   Source Headline
28th Jul 20157:01 amRNS£1 million seed investment in Inflowmatix
27th Jul 20157:00 amRNS£3.0 million investment in Concirrus
23rd Jul 20151:35 pmRNSDirectorate Change
14th Jul 20157:00 amRNSFurther £50m loan facility from EIB
2nd Jul 20157:00 amRNS£4.0m funding round in Impression Technologies
1st Jul 20157:00 amRNSFirst subject enrolled in Veryan Medical's study
30th Jun 20157:00 amRNSLeads £3 million investment in Abingdon Health
8th Jun 20151:18 pmRNSDirectorate Change
3rd Jun 20157:00 amRNSInnovations leads £6m funding round in Auspherix
29th May 20157:00 amRNSAppointment of Executive Chairman at Kesios
27th May 20154:05 pmRNSHolding(s) in Company
26th May 20157:01 amRNSDivests its shares of Epigeum
19th May 20157:00 amRNS£25m Series C funding round in PsiOxus
14th May 20157:00 amRNSTopiVert starts Phase I Clinical Trial
30th Apr 20153:48 pmRNSDirector's share purchase
27th Apr 20157:00 amRNSAutifony Therapeutics recruits first trial patient
15th Apr 20157:00 amRNSInnovations leads £5.9m funding round in Yoyo
27th Mar 20157:00 amRNSHalf Yearly Report
24th Mar 20154:40 pmRNSSecond Price Monitoring Extn
24th Mar 20154:35 pmRNSPrice Monitoring Extension
18th Mar 20157:00 amRNSCell Medica granted Orphan Drug designation
13th Mar 201510:07 amRNSEdison publishes research on Imperial Innovations
27th Feb 201511:48 amRNSNotice of Results
19th Feb 20157:00 amRNSCell Medica to commence cell therapy manufacture
14th Jan 201512:13 pmRNS£18 million Series B funding round in Veryan
18th Dec 20147:00 amRNSImperial named UK's top research university
16th Dec 201411:39 amRNSResult of AGM
9th Dec 20142:55 pmRNSGrant of options under SAYE Scheme
26th Nov 20143:41 pmRNSGrant of share options
25th Nov 201410:45 amRNSReplacement Director's share purchase
25th Nov 20147:00 amRNS£50 million Series B funding round in Cell Medica
24th Nov 20144:20 pmRNSDirector's share sale
12th Nov 20147:00 amRNSPosting of Annual Report and Notice of AGM
24th Oct 20147:00 amRNSDirectorate Changes
15th Oct 20147:00 amRNSFinal Results
8th Oct 20147:00 amRNSInnovations invests £1.85m in Kesios Therapeutics
5th Sep 20141:55 pmRNSNotice of Results
13th Aug 201412:43 pmRNSDirector's share sale
15th Jul 20142:08 pmRNSDirectorate Change
7th Jul 20147:14 amRNSPortfolio company Abzena announces offer price
4th Jul 20143:36 pmRNSHolding(s) in Company
23rd Jun 20143:15 pmRNSResults of Placing
23rd Jun 20147:00 amRNSPlacing to raise £150 million
19th Jun 201412:45 pmRNSResult of General Meeting
16th Jun 20147:09 amRNSPortfolio company announces intention to float
12th Jun 20147:00 amRNSImperial Innovations invests £1.5m in Cortexica
10th Jun 20147:00 amRNS£3 million funding round for Featurespace
4th Jun 20147:00 amRNSAutifony receives funding for Phase II trial
2nd Jun 20147:00 amRNSAppointment of non-executive directors
2nd Jun 20147:00 amRNSProposed Placing to raise up to £150 million

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.